Back to search results

MOv19-BBz CAR T Cells for FRa+ Lung Cancer

This study is testing a new treatment called MOv19-BBz CAR T cells for people with metastatic (spread to other parts of the body) or recurrent (returned after treatment) non-small cell lung cancer that has a specific marker called FRa. To join, your tumor must show FRa expression. This treatment involves taking your own immune cells, modifying them in a lab, and then giving them back to you. Before receiving the MOv19-BBz CAR T cells, you will get chemotherapy (Cyclophosphamide/Fludarabine) to prepare your body. The main goals of this study are to see how safe the treatment is and if it causes any serious side effects. This study aims to enroll 10 participants, but its current recruitment status is unclear.

Study design
This is a Phase I, open-label study, meaning both you and your doctors will know which treatment you are receiving. It is designed to enroll 10 participants.
What's involved
You will receive a single dose of MOv19-BBz CAR T cells through a tube placed in your chest cavity, after receiving chemotherapy. If you don't already have one, a temporary tube will be placed for the study.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for side effects for up to 15 years after receiving the MOv19-BBz CAR T cells.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07116057

MOv19-BBz CAR T Cells in FRa+ Cancers

Recruiting
PHASE1Ages 18+InterventionalTreatment
University of Pennsylvania
~10 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:MOv19-BBz CAR T cellsCyclophosphamide/FludarabineFRa Expression Testing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events as assessed by CTCAE V5.0
Measured over Up to 15 years post-MOv19-BBz CAR T cell administration
+1 more outcome measured

Conditions

Metastatic Non Small Cell Lung Cancer
Recurrent Lung Non-Small Cell Carcinoma

Explore related trials

Lung Non-Small Cell CarcinomaFOSL1 wt Allele

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Andrew Haas, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

Abramson Cancer Center Clinical Trials Service
[email protected]
215-349-8245
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of adverse events as assessed by CTCAE V5.0Up to 15 years post-MOv19-BBz CAR T cell administration

    Type, frequency, severity, and attribution of adverse events.

  • Occurrence of treatment-limiting toxicities (TLTs)28 days post-MOv19-BBz CAR T cell administration

    Unacceptable toxicity as defined by the protocol.